DxS appoints non-executive director
This article was originally published in Scrip
DxS (UK), a personalised medicine company, has appointed Ron Long non-executive director. He formerly worked at Amersham as commercial director, eventually serving as CEO for Amersham Pharmacia Biotech and vice-chairman of Amersham before retiring from the company in June 2001. Mr Long also worked at the Wellcome Foundation for more than 22 years.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.